Anchiano Therapeutics Reports First Quarter 2019 Financial Results
– Closed $30.5 million U.S. Initial Public Offering in February 2019 – CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery …